Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility

From General Skin Health to Occupational Exposure Concerns

The legacy of general health and science information has long emphasized the importance of skin integrity and the biological processes of aging, often through the lens of anti-aging skincare. This heritage provides a foundational understanding of how external factors interact with the body's largest organ, highlighting the skin's role as both a protective barrier and a site of vulnerability. Within this broad context, discussions of cellular turnover, immune surveillance, and environmental exposures have been central to public health messaging. Transitioning from this general health perspective to a more specific occupational exposure concern requires a shift in focus. In mass production settings, workers may encounter a range of chemical agents, including therapeutic compounds such as Avelumab, which is used in oncology. The biological plausibility of a link between Avelumab exposure and Merkel Cell Carcinoma risk emerges from the intersection of immunomodulation and carcinogenesis. Avelumab, as an immune checkpoint inhibitor, alters the body's natural immune response, potentially disrupting the delicate balance that prevents malignant transformation. In an occupational context, repeated or prolonged exposure to such agents could theoretically influence the skin's microenvironment, raising questions about long-term risk. This pivot from general skin health to the specific hazards of industrial exposure underscores the need for careful monitoring and risk assessment in environments where such compounds are handled.

Understanding Avelumab: Mechanism and Therapeutic Use

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096; https://pubmed.ncbi.nlm.nih.gov/33439294). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). Despite this therapeutic benefit, the biological plausibility of avelumab causing or contributing to MCC must be examined through mechanistic pathways, clinical presentation, and risk considerations.

Merkel Cell Carcinoma Etiology and Avelumab's Role

Merkel cell carcinoma has a known etiology: approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment for metastatic MCC includes anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer duration of responses compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385). However, about 50% of patients do not respond to these agents or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385). The biological plausibility of avelumab causing MCC is not supported by a direct carcinogenic mechanism; rather, avelumab is used to treat existing MCC. The drug’s mechanism—blocking PD-L1 to enhance T-cell activity—can lead to immune overactivation, as seen in reported irAEs such as hypercalcemia due to reactivation of sarcoidosis during avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781). This immune activation does not initiate MCC but may influence the tumor microenvironment in patients with pre-existing disease.

Clinical Evidence and Risk Considerations

Clinical presentation and diagnosis of MCC involve a rare, aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). In patients treated with avelumab, the drug is administered for metastatic MCC, and the timeline between exposure and harm is typically related to treatment response or adverse events rather than causation of the cancer itself. For avelumab-refractory patients, subsequent treatment with ipilimumab plus nivolumab has shown responses in some cases, indicating that avelumab does not universally worsen the disease but may fail to control it (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). The risk of avelumab causing MCC is not biologically plausible because the drug is an immunotherapy that targets PD-L1, a pathway often exploited by tumors to evade immune detection. In MCC, PD-L1 expression is common, and avelumab’s action is intended to reverse immune evasion, not induce malignancy. Risk anchors include the adequacy of warnings regarding avelumab and MCC. Current prescribing information and clinical guidelines recognize avelumab as a treatment for metastatic MCC, not as a causative agent. The drug’s label includes warnings about immune-related adverse events, but there is no evidence to suggest that avelumab causes MCC. Causation-related considerations for affected patients focus on the drug’s role in managing the disease rather than inducing it. The timeline between exposure and documented harm is typically measured in terms of treatment response or irAEs, which can occur weeks to months after initiation. For example, hypercalcemia due to sarcoidosis reactivation was managed with corticosteroids, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781). This supports the view that avelumab does not cause MCC but may trigger immune-related events in patients with underlying conditions.

Conclusion: No Evidence of Causation

In summary, the biological plausibility of avelumab causing Merkel cell carcinoma is not supported by evidence. The drug is an approved treatment for metastatic MCC, and its mechanism of action—PD-L1 inhibition—is directed against an immune checkpoint exploited by the tumor. While avelumab can cause immune-related adverse events, these do not include the initiation of MCC. The evidence indicates that avelumab is used to treat existing MCC, and any harm is related to treatment failure or irAEs, not causation of the cancer itself.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, there is no evidence that avelumab causes Merkel cell carcinoma. Avelumab is an immunotherapy used to treat existing metastatic MCC. Its mechanism of action targets PD-L1 to enhance immune response against tumor cells, not to initiate cancer. Studies show that avelumab does not induce MCC but may cause immune-related adverse events in some patients.

What is the biological plausibility of avelumab-related Merkel cell carcinoma?

The biological plausibility is not supported. Avelumab is a PD-L1 inhibitor that reverses immune evasion by tumors. While it can cause immune overactivation, this does not lead to the initiation of MCC. The known causes of MCC are Merkel cell polyomavirus and UV-induced mutations, not avelumab exposure.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.